Resumen

OCHOA, Julián et al. Clinical outcomes in cohor of patients with acute coronary syndrome and intracoronary tirofiban administration. Rev. Colomb. Cardiol. [online]. 2015, vol.22, n.1, pp.6-13. ISSN 0120-5633.  https://doi.org/10.1016/j.rccar.2015.03.002.

Introduction: Glycoprotein IIb/IIIa receptor inhibitors reduce major adverse cardiovascular events (MACE) in patients with acute coronary syndrome. Objective: To determine the major adverse cardiovascular events and safety of intracoronary and intravenous tirofiban in patients with acute coronary syndrome with percutaneous coronary intervention (PCI) compared to a group of patients without this medication. Material and methods:rospective cohort. Adults with acute coronary syndrome from January 2010 to December 2012 were included. A proportional hazard regression model after 1 month of follow up where the risk of MACE and the interest variable was intracoronary and intravenous tirofiban were assessed. Results: 382 patients were included. 46% (174 patients) received intracoronary tirofiban. The average age was 65 years vs. 60 years in the group of non-tirofiban users (p = 0.00). The rate of MACE at the first month was od 13/1000 events and 15/1000 events respectively in the group tirofiban and non-tirofiban (log rank test 0,935). The tirofiban use was neither related to a lower incidence of MACE (HR 1.09 95% IC 0.72 1.65) nor to major bleeding after the first month of follow up (1.72% vs. 2.88% respectively, p = 0.456). Conclusions: Intracoronary and intravenous tirofiban in patients with acute coronary syndrome was neither related to lower incidence of MACE nor to bleeding events; however, it should be taken into account that other clinical variables and the severity of unquantified coronary events might influence the results.

Palabras clave : Fibrinolytic agents; Platelet aggregation inhibitors; Acute coronary syndrome; Percutaneous coronary intervention.

        · resumen en Español     · texto en Español     · Español ( pdf )